article
Trastuzumab: Antineoplastic agent; a recombinant DNA-derived humanized anti-HER2 monoclonal antibody
International journal of applied research · 2015 · Vol. 1(10) · pp. 747–750
Abstract
Herceptin contains the active substance trastuzumab (anti-p185, rhuMab HER2), which is a humanised monoclonal antibody that binds to the HER2 protein. Trastuzumab received marketing approval from the US Food and Drug Administration Sep. 25, 1998 for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein. This review describes the overview of trastuzumab including mechanism of action, indications and adverse reactions.
HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchAdvanced Biosensing Techniques and ApplicationsTrastuzumabMonoclonal antibodyMedicineMetastatic breast cancerRecombinant DNAPharmacologyMonoclonalAntibodyHumanized antibodyDrug
Citations
0
FWCI
0.00
field-weighted impact
References
11
Percentile
26%
vs. same field & year
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.